Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BAK | 6-K | bearish | 9/10 | Braskem S.A. filed an Extrajudicial Restructuring Plan (standstill) in a Brazilian court and via a 6-K, confirming a sig | Aug 25, 2026 |
| IXHL | 8-K | bullish | 5/10 | Incannex Healthcare announced the first patient dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obst | Aug 25, 2026 |
| SGMT | PRESS-RELEASE | neutral | 4/10 | Sagimet announced its AURORA Phase 3 trial of denifanstat for moderate-to-severe acne is on track to begin enrollment in | Aug 25, 2026 |
| ARCT | 8-K | neutral | 3/10 | Arcturus Therapeutics presented a poster on its ARCT-810 mRNA therapy for Ornithine Transcarbamylase (OTC) Deficiency at | Aug 25, 2026 |
| BRNS | 8-K | mixed | 7/10 | Barinthus Biotherapeutics (BRNS) is being acquired by Clywedog Therapeutics in an all-stock transaction. The company has | Aug 25, 2026 |
| QNCX | EFFECT | bearish | 5/10 | Quince Therapeutics' S-3 shelf registration (File No. 333-297903) became effective on August 24, 2026. The shelf registe | Aug 25, 2026 |
| EPRX | EFFECT | bearish | 5/10 | Eupraxia Pharmaceuticals' SEC registration statement (File No. 333-298036) became effective on August 24, 2026. The fili | Aug 25, 2026 |
| RGEN | S-4 | neutral | 6/10 | Repligen filed an S-4 registration statement for its acquisition of BioLife Solutions (BLFS). BioLife stockholders will | Aug 25, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem S.A. filed a 6-K disclosing that it has initiated a Brazilian extrajudicial restructuring proceeding (recuperaçã | Aug 25, 2026 |
| STLN | CLUSTER | neutral | 3/10 | Two insiders at Starling Oncology traded in opposite directions within a week: Director Brad Hively sold $1.95M worth of | Aug 25, 2026 |
| ETON | CLUSTER | bearish | 5/10 | Eton Pharmaceuticals CEO Sean Brynjelsen sold ~$6.1M worth of stock over three days (Aug 19-20), and CBO David Krempa so | Aug 25, 2026 |
| MEDP | CLUSTER | neutral | 4/10 | Three Medpace insiders, including the CEO and CFO, sold a combined $26.4M in open-market shares over two days. The CEO a | Aug 25, 2026 |
| KURA | CLUSTER | bullish | 6/10 | Kura Oncology CEO Troy Wilson purchased $1.24M in open-market shares at ~$12.39, while the Chief Legal Officer and Chief | Aug 25, 2026 |
| ABCL | CLUSTER | mixed | 5/10 | Two directors at AbCellera made open-market purchases totaling $681K, with the largest buy ($570K) occurring 13 days aft | Aug 25, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$1.1M in open-market sales over two days. The CEO's sales foll | Aug 25, 2026 |
| APLM | CLUSTER | bullish | 8/10 | Three C-suite insiders at Apollomics Inc. (APLM) collectively purchased $2.25M of stock at $15.00/share over a 4-day win | Aug 24, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Three insiders at Arcutis Biotherapeutics sold a total of $198K in open-market sales over a 7-day window, with the large | Aug 24, 2026 |
| JUNS | 8-K | bearish | 6/10 | Jupiter Neurosciences completed a registered direct offering of 307,692 shares at $6.50/share for ~$2.0M in gross procee | Aug 24, 2026 |
| VNRX | 8-K | bearish | 6/10 | VolitionRx issued 773,361 shares of common stock to Lind Global Asset Management XII LLC in August 2026 to satisfy $400, | Aug 24, 2026 |
| GRML | 424B5 | bearish | 6/10 | Greenland Mines Ltd filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $50 million | Aug 24, 2026 |
| GRDX | S-1/A | bearish | 7/10 | GridAI Technologies Corp. filed Amendment No. 3 to its S-1 registration statement to register the resale of up to 9,908, | Aug 24, 2026 |
| ACOG | INSIDER-BUY | neutral | 3/10 | Director Robert James Wills purchased 10,000 shares of Alpha Cognition Inc. (ACOG) on the open market for $96,200 at $9. | Aug 24, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Aug 24, 2026 |
| GSK | 6-K | neutral | 2/10 | GSK's US President, Maya Martinez-Davis, sold a total of 44,397 American Depositary Shares (ADS) over two days (Aug 20-2 | Aug 24, 2026 |
| GRML | PRESS-RELEASE | bullish | 7/10 | Greenland Mines announced a landmark S-K 1300 Technical Report Summary for its Sarfartoq Nd-Pr Rare Earths Project, prep | Aug 24, 2026 |
| BETRF | 6-K | mixed | 5/10 | BetterLife Pharma appointed Dr. Mahan Chehrenama as Chief Medical Officer to lead BETR-001 clinical development toward a | Aug 24, 2026 |
| MCRB | EFFECT | bearish | 5/10 | Seres Therapeutics' S-3 shelf registration (File No. 333-298309) was declared effective by the SEC on August 21, 2026. T | Aug 24, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced the FDA has accepted for priority review a supplemental Biologics License Application for Jemperli (dostar | Aug 24, 2026 |
| CTKB | 8-K | bearish | 7/10 | Cytek disclosed a jury verdict in a patent infringement case brought by Beckman Coulter. The jury found in Cytek's favor | Aug 24, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced two positive regulatory milestones on August 24, 2026: Japan's MHLW approved Hibsago (bepirovirsen) as the | Aug 24, 2026 |